• Pfizer and BioNTech expect to produce up to 2 billion doses of their coronavirus vaccine in 2021.
  • This could bring Pfizer revenues of around $15 billion, the US pharmaceutical giant said Tuesday.
  • Pfizer's fourth-quarter revenues were up 12% year-over-year.
  • Visit Business Insider's homepage for more stories.

US pharmaceutical giant Pfizer expects the coronavirus vaccine it developed with BioNTech, the first to be authorized for emergency use in the West, to make it about $15 billion in revenues in 2021.

The company expects to produce up to 2 billion doses of the vaccine in 2021, based on its updated six-dose label, it said Tuesday. By January 31, it had already supplied 65 million doses of its vaccine globally, with close to half going to the US.

This 2 billion primarily included doses expected to be delivered under existing contracts, and could be higher if new contracts are added, it said.

Pfizer posted fourth-quarter revenues of $11.7 billion, up 12% year-over-year, including $154 million in sales of its coronavirus vaccine.

Its full-year revenues rose 2% to $41.9 billion.

The company forecasted revenues of between $59.4 and $61.4 billion for 2021. Most of this roughly 44% year-on-year growth would be generated through the additional $15 billion in revenues from its coronavirus vaccine, it said.

Adjusted income before tax margin for the vaccine would likely be just shy of 30%, it added.

The past year saw "the culmination of Pfizer's decade-long conversion into a pure-play, science, and innovation-focused company," CEO Dr. Albert Bourla said on Tuesday, calling it "a transformational year" for both Pfizer and the world.

"Our record-breaking success at developing a vaccine against Covid-19, along with our partner BioNTech, is just one example of what we believe this new Pfizer is capable of achieving," he added.

Read the original article on Business Insider

Receive a daily news update on your cellphone. Or get the best of our site emailed to you

Go to the Business Insider front page for more stories.